Press Release

TM3 Therapeutics Appoints Peter Van Vlasselaer as Chairman of the Board

By November 29, 2017 No Comments

Current ARMO BioSciences CEO Brings Profound Drug Development, Operations & Strategy Expertise to TM3

 

LEIDEN, The Netherlands, November 29, 2017 – TM3 Therapeutics, a biopharmaceutical company developing metabolite replacement therapies for rare, genetic neurological diseases, today announced the appointment of Peter Van Vlasselaer, Ph.D. as Chairman of TM3’s Board of Directors.  Dr. Van Vlasselaer is a serial entrepreneur with an outstanding track record of building successful biotechnology companies. He is bringing more than 20 years of senior management experience to TM3 and will actively guide the company on a number of activities including drug development as well as corporate strategy.

“As co-founder, CEO and board member of several biotechnology companies, Peter has extensive experience in guiding companies from their early innovative research stage through commercialization of therapies. His insights will be invaluable to us as we accelerate our drug candidate towards the clinic, to bring an effective treatment option for patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN), a rare, hereditary disorder,” said Enej Kuscer, Ph.D., CEO of TM3. “Being able to recruit a seasoned industry expert such as Peter is a great achievement for TM3 and speaks to our vision for the company and the strategies we have in place. We are thrilled to welcome Peter as Chairman of our Board and look forward to his contributions as we position the company for success.”

Peter Van Vlasselaer, Ph.D. commented: “TM3 is emerging as one of the exciting new companies to treat rare diseases with significant unmet medical need. The Company’s unique focus on compensating for impaired metabolic pathways is applied to a a number of rare disease indications, and their deep understanding of coenzyme A biology has resulted in a very promising therapeutic approach to treat PKAN as its front-runner. I strongly believe in the potential of TM3’s approach and look forward to working with the management team as they develop strategies towards a number of effective treatment options for patients with inborn errors of metabolism.

During his career, Dr. Van Vlasselaer has contributed to the development of multiple biologic products and small molecules for treating diseases including cancer, inflammation, infectious diseases and fibrosis. He has authored several peer-reviewed scientific articles and book chapters and is the inventor on more than 30 patents.

Currently, Dr. Van Vlasselaer is Co-founder and CEO of ARMO BioScience, a US-based immuno-oncology company that is evaluating a long-acting form of recombinant human Interleukin 10 (IL-10) currently in Phase-3 trials. He previously served as Executive Chairman and interim CEO of iPierian and was the founding CEO of Arresto Biosciences, which was acquired by Gilead Sciences in December 2010.  Prior to launching Arresto, Dr. Van Vlasselaer was the CEO of Avidia which also had a successful exit though its sale to Amgen in October 2006.  Before that he was involved in the start-up of InterMune and Dendreon where he served as Senior Vice President of Technical Operations and Vice President of Development, respectively.  He holds a bachelor’s degree in zoology and a PhD in immunology from the University of Leuven in Belgium and conducted post-doctoral research at Stanford University and at DNAX Research Institute in Palo Alto, California.

About TM3 Therapeutics B.V.

TM3 Therapeutics’ purpose is to develop effective treatments for Inborn Errors in Metabolism, rare but severe metabolic and often neurological disorders that primarily affect children. Our lead program to treat PKAN addresses a novel target in the coenzyme A biosynthetic pathway, aiming to reverse the disease’s progressive loss of brain and muscle function. We founded TM3 to be an organization that works together with the leading academic researchers to bring innovative therapies to patients, their families and the medical professionals serving them.

Contacts

Enej Kuscer, Ph.D.
CEO, TM3 Therapeutics B.V.
enej.kuscer@tm3therapeutics.com
Tel: +386 40 414 818

MacDougall Biomedical Communications
Jacob Verghese, Ph.D. or Mario Brkulj
jverghese@macbiocom.com or mbrkulj@macbiocom.com
Tel: +49 (0) 89 2424 3494 or +49 (0) 89 24209345